核苷(酸)类似物联合聚乙二醇干扰素治疗慢性乙型肝炎的临床疗效分析

肝脏 ›› 2023, Vol. 28 ›› Issue (9): 1048-1049.

核苷(酸)类似物联合聚乙二醇干扰素治疗慢性乙型肝炎的临床疗效分析

蒋兆荣, 邹梅, 姬腾飞, 刘欢, 顾生旺, 冯伟广, 赵文玺

223001 江苏淮安八二医院感染内科

收稿日期:2022-11-16 出版日期:2023-09-30 发布日期:2023-10-24
通讯作者: 蒋兆荣,Email:1052489039@qq.com
基金资助:
中国慢乙肝临床治愈(珠峰)工程项目(肝基字2018第10号)

Clinical efficacy analysis of nucleoside (acid) analogues combined with polyethylene glycol interferon in the treatment of chronic hepatitis B

JIANG Zhao-rong, ZOU Mei, JI Teng-fei, LIU Huan, GU Sheng-wang, FENG Wei-guang, Zhao Wen-xi

Department of Infectious Diseases, Huai'an Medical District, General Hospital of the Eastern Theater Command, Jiangsu 223001,China

Received:2022-11-16 Online:2023-09-30 Published:2023-10-24
Contact: JIANG Zhao-rong,Email:1052489039@qq.com

摘要/Abstract

摘要： 目的观察聚乙二醇干扰素α-2b联合核苷(酸)类似物治疗慢性乙型肝炎的临床疗效。方法纳入淮安八二医院2017年1月至2022年6月慢性乙型肝炎患者,310例采用聚乙二醇干扰素α-2b联合核苷(酸)类似物治疗,作为观察组;仅采取核苷(酸)类似物治疗的310例患者作为对照组。观察两组的HBsAg转换率、HBV DNA转阴率以及肝功能复常率。结果观察组HBV DNA转阴率、ALT复常率、HBsAg转换率分别为301例(97%)、278例(89.7%)、120例(38.7%);对照组分别为288例(92.9%)、 243例(78.3%)、8例(2.58%),差异均有统计学意义(χ²=262.091、161.895、167.293,均P<0.01)。结论聚乙二醇干扰素α-2b联合核苷(酸)类似物治疗慢性乙型肝炎疗效显著。

关键词: 聚乙二醇干扰素α-2b, 核苷(酸)类似物, 慢性乙型肝炎, 乙型肝炎表面抗原, 乙型肝炎病毒

Abstract: Objective To study the clinical cure effect of polyethylene glycol interferon α-2b in combination with nucleotide (acid) analog in the treatment of chronic hepatitis B.Methods Three hundred and ten patients with chronic hepatitis B enrolled during January 1, 2017 to June 30, 2022 were given polyethylene glycol interferon α-2b plus nucleoside (acid) analogue and set as the observation group. Another 310 patients previously treated with nucleotide (acid) analogue were taken as the control group. The HBsAg conversion rate, HBV DNA conversion rate and liver function regaining rate in both groups were compared. Results HBV DNA conversion, liver function regaining rate and HBsAg conversion rate in the observation group were 301 (97%), 278 (89.7%), 120 (38.7%), respectively, which were statistically significant different with those of 288 (92.98%), 243 (78.3%), 8 (2.58%) in the control group (χ²=262.091/161.895/167.293, all P<0.01). Conclusion The combination of polyethylene glycol interferon α -2b and nucleoside (acid) analogue is very effective in reducing the level of hepatitis B virus, and promoting liver function normalization in the treatment of chronic hepatitis B.

Key words: Polyethylene glycol, Nucleoside (acid) analogues, Chronic hepatitis B, HBsAg, Hepatitis B virus

蒋兆荣, 邹梅, 姬腾飞, 刘欢, 顾生旺, 冯伟广, 赵文玺. 核苷(酸)类似物联合聚乙二醇干扰素治疗慢性乙型肝炎的临床疗效分析[J]. 肝脏, 2023, 28(9): 1048-1049.

JIANG Zhao-rong, ZOU Mei, JI Teng-fei, LIU Huan, GU Sheng-wang, FENG Wei-guang, Zhao Wen-xi. Clinical efficacy analysis of nucleoside (acid) analogues combined with polyethylene glycol interferon in the treatment of chronic hepatitis B[J]. Chinese Hepatolgy, 2023, 28(9): 1048-1049.

参考文献

[1] 中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2019年版).肝脏,2019,24:1335-1336.
[2] Terrault NA, Lok ASF, McMahon BJ, et al, Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 Hepatitis B Guidance, Hepatology, 2018, 67: 1560-1599.
[3] European Association for the Study of the Liver, EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol, 2017, 67: 370-398.
[4] 毛天皓,刘天旭,鲁凤民.乙型肝炎病毒黄价闭合环状DNA形成机制的研究进展.肝脏,2021,26:223-225.
[5] 中华医学会感染病分会,中华医学会肝病学分会. 慢性乙型肝炎临床治愈(功能性治愈)专家共识.中华肝脏病杂志,2019,27:594-603.
[6] 张晓艳,张海涛,杨立新,孟娟,巩春燕.恩替卡韦联合长效干扰素治疗HBeAg阳性慢性乙型肝炎临床研究.中国药业,2019,28(18):35-37.
[7] 涂杰霞,王安娜,廖若汐.干扰素α-2b与聚乙二醇干扰素α-2a治疗慢性乙型肝炎患者疗效比较研究.实用肝脏病杂志,2019,22(05):648-651.
[8] 张珊,王艺璇,孙静,朱琳,王凤水,邢卉春.干扰素联合抗病毒治疗对提高核苷(酸)类药物经治慢性乙型肝炎患者表面抗原阴转率的影响.中华实验和临床感染病杂志(电子版),2019,13(04):273-280.
[9] 唐晓雯,卢根娣,张雅丽.干扰素治疗慢性乙型肝炎健康教育模式的研究进展.中国当代医药,2019,26(22):19-22.
[10] 丁小龙,景顺萍.恩替卡韦联合聚乙二醇干扰素治疗慢性乙型肝炎患者的疗效分析.实用临床医药杂志,2019,23(13):18-22.
[11] 蒋兆荣,张金荣,余亚新,等. 恩替卡韦联合聚乙二醇干扰素a-2a治疗难治性慢性乙型肝炎HBeAg血清学转换疗效观察.肝脏,2016,21:644-647.
[12] 高志良.慢性乙型肝炎功能性治愈(临床治愈)的热点和难点.现代消化及介入诊疗.2019,9:949-951.
[13] 宁琴.慢性乙型肝炎临床治愈(功能性治愈)专家共识.中华肝脏病杂志,2019,8:594－603.
[14] 应玲玲,章国君,叶卫江。干扰素治疗慢性乙型肝炎的研究进展。国际流行病学传染病学杂志,2020,6:559－564.
[15] 蒋兆荣,顾生旺,邹梅,等. 恩替卡韦经治1年后加用干扰素a-2b临床治愈30例分析.肝脏,2021,26:316-317.